- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FDA Approves Tubeless Option for Tandem Mobi Insulin Pump

The US FDA has approved a tubeless cartridge and infusion set for the Tandem Mobi insulin pump, offering users the flexibility to choose between tubed and tubeless insulin delivery.
The system incorporates Control-IQ+ technology, which predicts glucose levels and automatically adjusts insulin delivery to help maintain glycaemic control.
The tubeless option is expected to become available through pharmacies in the first half of 2027.This approval expands insulin delivery choices for people with diabetes, potentially improving convenience, flexibility and adherence to automated insulin therapy.
“The Tandem Mobi insulin pump was originally designed to make different wear options possible, which now includes a tubeless option with up to 7 days of wear1,” said John Sheridan, president and chief executive officer. “This clearance of the Tandem Mobi tubeless cartridge and infusion set creates even more possibilities for people living with diabetes, expanding the number of ways to experience the proven benefits of our Control-IQ+ AID technology.”
Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi is planned for the first half of 2027 in the United States. Customers with an in-warranty Tandem Mobi will not need a new insulin pump. Existing Tandem Mobi pumps are already compatible and can be used with the new tubeless infusion set and cartridge. Tandem will contact eligible customers with information about how to access the sets and cartridges when they are available.
Tandem Mobi Tubeless infusion sets and cartridges will be available exclusively through the pharmacy for customers with pharmacy benefits. Tandem currently estimates that pharmacy coverage for Tandem Mobi customers is available for approximately 50% of insured lives in the United States, with continued expansion expected ahead of launch and throughout 2027.
About the Tandem Mobi System
Tandem Mobi is the world’s smallest insulin pump that can be worn tubed or tubeless. Powered by Control-IQ+ technology, it uses CGM sensor values to predict glucose levels 30 minutes ahead and automatically adjust insulin as needed, with AutoBolus™ to help prevent hyperglycemia. Tandem Mobi can be used with compatible smartphones via the Tandem Mobi mobile app and supports multiple wear options including tubed and tubeless. Compatible with all Tandem infusion sets, the system allows users to temporarily disconnect for showering, hot tubs, or contact sports. It includes a 200-unit cartridge, inductive charging, water resistance (IP28), remote software updates, and wireless uploads of pump and therapy data to the cloud-based Tandem Source platform.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

